TY - JOUR
T1 - Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome
AU - Carmona-Iragui, María
AU - O'Connor, Antoinette
AU - Llibre-Guerra, Jorge
AU - Lao, Patrick
AU - Ashton, Nicholas J.
AU - Fortea, Juan
AU - Sánchez-Valle, Raquel
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/10
Y1 - 2024/10
N2 - Autosomal dominant Alzheimer's disease (ADAD) and Down syndrome (DS) constitute genetic forms of Alzheimer's disease (AD). The study of these forms has been crucial in understanding the biomarker changes and disease progression, notably in advancing our knowledge of the natural history of AD. However, some specific characteristics of biomarkers in genetically determined forms and, most importantly, the near full penetrance and predictability of disease onset lead to a very different context of use for biomarkers in these populations. This article delves into the similarities and differences in biomarker profiles between genetically determined AD and sporadic cases, discussing the implications for research and clinical practice. It also emphasizes the need to account for factors that may affect biomarker reliability differently in genetically determined AD. Enhancing our understanding of the disease will pave the way for more personalized therapeutic approaches for affected individuals.
AB - Autosomal dominant Alzheimer's disease (ADAD) and Down syndrome (DS) constitute genetic forms of Alzheimer's disease (AD). The study of these forms has been crucial in understanding the biomarker changes and disease progression, notably in advancing our knowledge of the natural history of AD. However, some specific characteristics of biomarkers in genetically determined forms and, most importantly, the near full penetrance and predictability of disease onset lead to a very different context of use for biomarkers in these populations. This article delves into the similarities and differences in biomarker profiles between genetically determined AD and sporadic cases, discussing the implications for research and clinical practice. It also emphasizes the need to account for factors that may affect biomarker reliability differently in genetically determined AD. Enhancing our understanding of the disease will pave the way for more personalized therapeutic approaches for affected individuals.
KW - Alzheimer
KW - Autosomal dominant Alzheimer's disease
KW - Biofluids
KW - Biomarkers
KW - Down syndrome
UR - http://www.scopus.com/inward/record.url?scp=85205711683&partnerID=8YFLogxK
U2 - 10.1016/j.ebiom.2024.105327
DO - 10.1016/j.ebiom.2024.105327
M3 - Review article
C2 - 39366843
AN - SCOPUS:85205711683
SN - 2352-3964
VL - 108
JO - EBioMedicine
JF - EBioMedicine
M1 - 105327
ER -